Literature DB >> 29153425

Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2.

Emily R Hankosky1, Shyam R Joolakanti2, Justin R Nickell1, Venumadhav Janganati2, Linda P Dwoskin1, Peter A Crooks3.   

Abstract

A small library of fluoroethoxy-1,4-diphenethyl piperidine and fluoroethoxy-1,4-diphenethyl piperazine derivatives were designed, synthesized and evaluated for their ability to inhibit [3H]dopamine (DA) uptake at the vesicular monoamine transporter-2 (VMAT2) and dopamine transporter (DAT), [3H]serotonin (5-HT) uptake at the serotonin transporter (SERT), and [3H]dofetilide binding at the human-ether-a-go-go-related gene (hERG) channel. The majority of the compounds exhibited potent inhibition of [3H]DA uptake at VMAT2, Ki changes in the nanomolar range (Ki = 0.014-0.073 µM). Compound 15d exhibited the highest affinity (Ki = 0.014 µM) at VMAT2, and had 160-, 5-, and 60-fold greater selectivity for VMAT2 vs. DAT, SERT and hERG, respectively. Compound 15b exhibited the greatest selectivity (>60-fold) for VMAT2 relative to all the other targets evaluated, and 15b had high affinity for VMAT2 (Ki = 0.073 µM). Compound 15b was considered the lead compound from this analog series due to its high affinity and selectivity for VMAT2.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dopamine uptake; Fluoroethoxy piperidine and piperazine analogs; Lobelane; VMAT2; hERG

Mesh:

Substances:

Year:  2017        PMID: 29153425      PMCID: PMC5782818          DOI: 10.1016/j.bmcl.2017.10.039

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

1.  Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.

Authors:  A G Teschemacher; E P Seward; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

2.  Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT.

Authors:  M Iyo; H Namba; M Yanagisawa; S Hirai; N Yui; S Fukui
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1997-07       Impact factor: 5.067

3.  Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Guangrong Zheng; Agripina G Deaciuc; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-09-28       Impact factor: 4.030

Review 4.  Major physical and psychological harms of methamphetamine use.

Authors:  Shane Darke; Sharlene Kaye; Rebecca McKetin; Johan Duflou
Journal:  Drug Alcohol Rev       Date:  2008-05

Review 5.  A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.

Authors:  Linda P Dwoskin; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2002-01-15       Impact factor: 5.858

6.  Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats.

Authors:  Dennis K Miller; Steven B Harrod; Thomas A Green; Mei-Yee Wong; Michael T Bardo; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2003-01       Impact factor: 3.533

7.  The relationship between methamphetamine use and increased dental disease.

Authors:  Vivek Shetty; Larissa J Mooney; Corwin M Zigler; Thomas R Belin; Debra Murphy; Richard Rawson
Journal:  J Am Dent Assoc       Date:  2010-03       Impact factor: 3.634

Review 8.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

Review 9.  Treatment for amphetamine withdrawal.

Authors:  Steven J Shoptaw; Uyen Kao; Keith Heinzerling; Walter Ling
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

10.  Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.

Authors:  Dennis K Miller; Peter A Crooks; Guangrong Zheng; Vladimir P Grinevich; Seth D Norrholm; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2004-04-30       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.